Repaglinide
- Generic Name
- Repaglinide
- Brand Names
- Enyglid, Gluconorm, Prandin, NovoNorm, Repaglinide Krka, Repaglinide Accord, Repaglinide Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C27H36N2O4
- CAS Number
- 135062-02-1
- Unique Ingredient Identifier
- 668Z8C33LU
- Background
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood ...
- Indication
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Study of Effects of Selpercatinib (LY3527723) on Repaglinide in Healthy Participants
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2022-07-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 13
- Registration Number
- NCT05469113
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study of Imlunestrant (LY3484356) in Female Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2022-11-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 113
- Registration Number
- NCT05444556
- Locations
- 🇺🇸
Altasciences Clinical Los Angeles, Inc, Cypress, California, United States
🇺🇸Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸ICON Early Phase Services, San Antonio, Texas, United States
Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2022-11-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 48
- Registration Number
- NCT05236530
- Locations
- 🇬🇧
Novartis Investigative Site, Belfast, Northern Ireland, United Kingdom
Drug-drug Interaction Study of KL1333 in Healthy Subjects
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2021-10-20
- Lead Sponsor
- Abliva AB
- Target Recruit Count
- 14
- Registration Number
- NCT04643249
- Locations
- 🇬🇧
Volunteer recruitment center Covance Leeds Covance Leeds, Leeds, United Kingdom
A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients With Advanced GIST
- Conditions
- Interventions
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 13
- Registration Number
- NCT04530981
- Locations
- 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects
- Conditions
- Interventions
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04457180
- Locations
- 🇨🇳
The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China
Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables
- Conditions
- Interventions
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2019-01-31
- Lead Sponsor
- University of Palermo
- Target Recruit Count
- 92
- Registration Number
- NCT03824002
- Locations
- 🇮🇹
Internal Medicine Ward, University of Palermo, Palermo, Italy
A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
- Conditions
- Interventions
- First Posted Date
- 2018-10-29
- Last Posted Date
- 2019-12-18
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT03723395
- Locations
- 🇺🇸
Covance Clinical Research Unit, Dallas, Texas, United States
Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy
- Conditions
- Interventions
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 384
- Registration Number
- NCT03359837
- Locations
- 🇨🇳
CHINA, China, China
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03028103
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.